Abstract 171P
Background
To evaluate the prognostic value of prognostic nutritional index(PNI)in esophageal cancer patients under minimally invasive esophagectomy (MIE) with peritoneal metastasis.
Methods
The clinical and pathological data of 197 patients under MIE with anastomotic leakage from January 2013 to December 2015 were analyzed retrospectively.
Results
PNI was not associated with various clinicopathological factors such as age, gender, smoking history, tumor location, tumor length, differentiation degree, T stage, N stage, treatment mode, TNM stage and lymph node metastasis rate (P > 0.05). Univariate survival analysis showed that male, smoking history, advanced tumor stage, tumor length>5cm, advanced N stage, higher lymph node metastasis rate, advanced TNM stage, and treatment modality were associated with poor prognosis. Multivariate analysis showed that N stage (HR = 6.108, CI:1.614-23.113, P = 0.008) and treatment modality (HR = 0.362, CI: 0.213-0.617, P < 0.001) are independent risk factors. PNI is not an independent risk factor.
Conclusions
Prognostic nutritional index is not an independent risk factor of the prognosis for patients under minimally invasive esophagectomy with anastomotic leakage. Treatment method and lymph node metastasis are still the main factors affecting long-term survival in this group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The 4th Hospital of Hebei Medical University.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract